AbbVie Inc. Announces Dividend Increase, Regulatory Approval, and Workplace Recognition

• Dividend Enhancement
  AbbVie Inc. has announced a quarterly dividend of $1.64 per share. The increase reflects the company’s ongoing commitment to delivering shareholder value and aligns with its status as a member of the S&P Dividend Aristocrats Index.

• Health Canada Approval of Elahere
  The company received Health Canada approval for Elahere, a treatment for ovarian cancer. This approval is expected to bolster AbbVie’s top‑line growth, particularly within its neuroscience portfolio, and expands the company’s therapeutic reach.

• Workplace Recognition
  AbbVie was named one of the best workplaces in Asia by Great Place to Work. The designation underscores the company’s focus on employee well‑being and a positive organizational culture.

• Clinical Trial Progress
  Updated data from the Phase 2 EPCORE NHL‑6 study indicate that outpatient monitoring is feasible for patients with relapsed or refractory diffuse large B‑cell lymphoma. The findings support AbbVie’s strategy to streamline treatment delivery and improve patient outcomes.

• Collaborative Trial Results
  In a related development, REGENXBIO presented positive results from a pivotal trial of RGX‑121, a therapy for mucopolysaccharidosis type II. The trial demonstrated significant reductions in key disease biomarkers, providing further evidence of the efficacy of novel therapeutics within the industry.

Implications for the Company
These announcements collectively signal AbbVie’s continued emphasis on shareholder returns, regulatory milestones, employee satisfaction, and clinical innovation. The company’s trajectory suggests sustained growth potential and a reinforced position within the biotechnology sector.